Enliven Therapeutics
Burlingame, California, United States · Biotechnology, Healthcare, Health Care
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from cl
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Burlingame, California, United States
- Employees
- 85
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (ELVN)
- Website
- www.enliventherapeutics.com
- Company page
Recent activity at Enliven Therapeutics
- : Enliven Therapeutics Appoints Kristine Ball as Class II Director
- : SEC 8-K (5.02): On October 14, 2026, Enliven Therapeutics, Inc. appointed Kristine Ball as a Class II director, increasing the board size from seven to eight members. Her term will expire at the Company’s 2028 annual meeting of stockholders, effective the same day. Ms. Ball will receive an annual cash compensation of $45,000 for serving as an outside director and an additional $10,000 for her role on the Audit Committee. She has been granted stock options with a fair value of approximately $650,000, which will vest monthly, subject to her continued service, and will fully vest in the event of a Change in Control. The Company also entered into its standard indemnification agreement with Ms. Ball.
- : SEC 8-K (1.01): On June 11, 2026, Enliven Therapeutics, Inc. entered into a Material Definitive Agreement through an underwriting agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Barclays Capital Inc. The agreement pertains to the public offering of 8,933,334 shares of the Company's common stock at a public offering price of $37.50 per share, along with pre-funded warrants for an additional 1,733,333 shares. The Company is expected to raise approximately $376.0 million, or $432.4 million if the underwriters fully exercise their option. The offering is set to close on June 15, 2026, contingent on customary closing conditions. This strategic move anticipates enhancing the Company’s financial position significantly, with the proceeds aimed at advancing its business goals.
About Enliven Therapeutics: questions and answers
What does Enliven Therapeutics do?
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from cl
Where is Enliven Therapeutics headquartered?
Enliven Therapeutics is headquartered in Burlingame, California, United States.
How many employees does Enliven Therapeutics have?
Enliven Therapeutics has about 85 employees.
What is the latest news on Enliven Therapeutics?
On Oct 14, 2026, Enliven Therapeutics Appoints Kristine Ball as Class II Director
Is Enliven Therapeutics a public company?
Yes. Enliven Therapeutics is publicly traded under the ticker ELVN.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy